Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 1.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,731 shares of the biopharmaceutical company’s stock after selling 17 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,666,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after acquiring an additional 39,780 shares during the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares during the last quarter. Putnam Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the last quarter. Northern Trust Corp boosted its holdings in Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares during the last quarter. Finally, Norges Bank purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $932,571,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.8 %

Regeneron Pharmaceuticals stock traded up $8.75 during midday trading on Friday, hitting $1,053.14. The stock had a trading volume of 1,291,712 shares, compared to its average volume of 370,351. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock has a market cap of $116.05 billion, a P/E ratio of 31.11, a P/E/G ratio of 2.16 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $1,059.80. The business has a fifty day moving average price of $967.84 and a 200 day moving average price of $942.68.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the sale, the chief executive officer now directly owns 64,198 shares of the company’s stock, valued at $65,162,253.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 787 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now owns 64,198 shares of the company’s stock, valued at $65,162,253.96. The disclosure for this sale can be found here. Insiders sold a total of 61,215 shares of company stock valued at $60,414,782 over the last three months. 7.48% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. Truist Financial reissued a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, UBS Group raised their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $998.09.

Read Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.